Se-DMC has antioxidant, anti-damage and anti-edema properties and can be used to study diseases related to metabolism and inflammation.

METHODS: Se-DMC (5 mg/kg; orally) and meloxicam (5 mg/kg; orally) were both given to mice daily for 14 days, and effects on paw edema, mechanical sensitivity, neurobehavioral deficits (anxiolytic and depressive-like behaviors), Na/K-ATPase activity, oxidative stress, and inflammation were evaluated in CFA-exposed (intramuscular injection 0.1 mL; 10 mg/mL) male Swiss mice were evaluated.
RESULTS: Se-DMC decreased paw withdrawal threshold and CFA-induced paw edema. Histopathological results revealed the anti-edema potential of the compound, with a lower number of dilated lymphatic vessels compared to the CFA group. se-DMC reduced the relative mRNA expression levels of tumor necrosis factor-α (TNF-α) and nuclear factor-κB (NF-κB) in the hippocampus and paw of CFA mice. CFA-induced anxiolytic and depressive-like behaviors in elevated plus-maze and tail-suspension tests were reversed to control levels by Se-DMC.Se-DMC decreased paw reactive substance levels and restored superoxide dismutase (hippocampus and paws) and Na/K-ATPase (hippocampus) activities previously increased by CFA. In addition, CFA administration inhibited serum creatinine kinase activity, although the Se-DMC effect did not appear to involve regulation of this enzyme and was equal to or greater than that of meloxicam.Se-DMC attenuated CFA-induced inflammatory responses, injury perception, and neurobehavioral deficits in mice. [1]

DMSO: 30 mg/mL (89.91 mM), Sonication is recommended.